STX Stock Overview
A commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Shield Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.027 |
| 52 Week High | UK£0.078 |
| 52 Week Low | UK£0.011 |
| Beta | 1.53 |
| 1 Month Change | -4.39% |
| 3 Month Change | -21.01% |
| 1 Year Change | -57.75% |
| 3 Year Change | -92.38% |
| 5 Year Change | -98.50% |
| Change since IPO | -98.26% |
Recent News & Updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Recent updates
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Shareholder Returns
| STX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.9% | -1.7% | -2.6% |
| 1Y | -57.8% | -3.5% | 2.4% |
Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: STX underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| STX volatility | |
|---|---|
| STX Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: STX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: STX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 73 | Anders Lundstrom | www.shieldtherapeutics.com |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc Fundamentals Summary
| STX fundamental statistics | |
|---|---|
| Market cap | UK£21.31m |
| Earnings (TTM) | -UK£28.76m |
| Revenue (TTM) | UK£17.08m |
1.2x
P/S Ratio-0.7x
P/E RatioIs STX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STX income statement (TTM) | |
|---|---|
| Revenue | US$21.47m |
| Cost of Revenue | US$13.65m |
| Gross Profit | US$7.83m |
| Other Expenses | US$43.99m |
| Earnings | -US$36.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 36.44% |
| Net Profit Margin | -168.42% |
| Debt/Equity Ratio | 3,637.5% |
How did STX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shield Therapeutics plc is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Stuart Harris | Cavendish |
| Alexander Pye | Cavendish |